Premium
Effects of growth hormone replacement therapy on lipids, lipoproteins and apolipoproteins: Is the increased apolipoprotein A‐1/B ratio the only benefit?
Author(s) -
Yildiz, Metin,
Arslanoglu, Ilknur,
Yildiz, Nurdan,
Nartop, Filiz,
Isik Kutay,
Isguven Pinar
Publication year - 2000
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1046/j.1442-200x.2000.01193.x
Subject(s) - medicine , apolipoprotein b , endocrinology , cholesterol
Background: The aim of the present study was to investigate the controversial role of growth hormone (GH) therapy in lipid regulation.Methods: We studied serum levels of cholesterol and subgroups, triglyceride and apolipoprotein A‐1 and B in 41 GH‐deficient children (with subgroups of untreated and short‐ and long‐term treated subjects) and 20 healthy controls.Results: Cholesterol and low‐density lipoprotein cholesterol levels (in mmol/L) were found to be 4.92~1.34 and 3.02~1.58 in untreated, 4.15~0.72 and 2.46~0.65 in short‐term (3 month) treated, 4.93~1.39 and 3.15~1.38 in long‐term (> 1 year) treated and 4.11~0.5 and 2.0~0.74 in control subjects, respectively. The apolipoprotein A‐1:B ratio was 1.98~0.5 in long‐term treated and 1.6~0.6 in control subjects.Conclusions: The improvement of lipid composition with short‐term GH therapy is temporary, but the increase in apo A‐1:B is not and seems to be the particular benefit of this therapy.